These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7542770)

  • 41. Comparison of the effects of the M1-receptor antagonist telenzepine and the CCK-receptor antagonist loxiglumide on the pancreatic secretory response to intraduodenal tryptophan in dogs.
    Teyssen S; Niebergall-Roth E; Rausch A; Beglinger C; Riepl RL; Chari S; Singer MV
    Pancreas; 1996 Nov; 13(4):407-16. PubMed ID: 8899802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan.
    Ochi K; Harada H; Satake K
    Digestion; 1999; 60 Suppl 1():81-5. PubMed ID: 10026438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of intrinsic CCK and CCK antagonist on pancreatic growth and pancreatic enzyme secretion in pancreaticobiliary diversion rats.
    Bamba T; Ishizuka Y; Hosoda S
    Dig Dis Sci; 1993 Apr; 38(4):653-9. PubMed ID: 7681747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats.
    Wang Y; Naruse S; Kitagawa M; Ishiguro H; Nakae Y; Yoshikawa T; Hayakawa T
    Pancreas; 1998 Oct; 17(3):289-94. PubMed ID: 9788544
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
    Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats.
    Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S
    Pancreas; 1995 Apr; 10(3):295-300. PubMed ID: 7542771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini].
    Fujii M; Otsuki M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
    Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):77-82. PubMed ID: 2471851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of protein derivatives on pancreatic secretion and release of secretin and CCK in rats.
    Shimizu K; Shiratori K; Watanabe S; Takeuchi T; Chang TM; Chey WY
    Am J Physiol; 1994 Oct; 267(4 Pt 1):G508-14. PubMed ID: 7943315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitory effects of the cholecystokinin antagonist loxiglumide on pancreatic exocrine secretion and pancreatic growth in conscious rats.
    Taguchi S; Green GM; Nakano I; Hatta Y
    Int J Pancreatol; 1992 Apr; 11(2):67-73. PubMed ID: 1607730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
    Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
    Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melatonin treatment is beneficial in pancreatic repair process after experimental acute pancreatitis.
    Sidhu S; Pandhi P; Malhotra S; Vaiphei K; Khanduja KL
    Eur J Pharmacol; 2010 Feb; 628(1-3):282-9. PubMed ID: 19958759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice].
    Kobayashi M; Shinagawa K; Sugiura M; Nagasawa T; Akahane M; Ajisawa Y
    Nihon Yakurigaku Zasshi; 1996 Apr; 107(4):183-95. PubMed ID: 8690301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
    Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
    Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of KSG-504, a new synthetic cholecystokinin receptor antagonist on ethionine-induced acute pancreatitis in rats].
    Okumura Y; Bamba T; Shintani Y; Yoshioka U; Inoue H; Fujiyama Y; Hosoda S
    Nihon Shokakibyo Gakkai Zasshi; 1993 Dec; 90(12):3032-40. PubMed ID: 8283814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cholecystokinin fails to promote pancreatic regeneration in diabetic rats following the induction of experimental pancreatitis.
    Takács T; Hegyi P; Jármay K; Czakó L; Góg C; Rakonczay Z; Németh J; Lonovics J
    Pharmacol Res; 2001 Nov; 44(5):363-72. PubMed ID: 11712866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of cholecystokinin-A (CCK-A) receptor in pancreatic regeneration after pancreatic duct occlusion: a study in rats lacking CCK-A receptor gene expression.
    Miyasaka K; Ohta M; Tateishi K; Jimi A; Funakoshi A
    Pancreas; 1998 Mar; 16(2):114-23. PubMed ID: 9510132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.
    Hildebrand P; Beglinger C; Gyr K; Jansen JB; Rovati LC; Zuercher M; Lamers CB; Setnikar I; Stalder GA
    J Clin Invest; 1990 Mar; 85(3):640-6. PubMed ID: 2312719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Inhibitory effect of CR 1409 (cholecystokinin antagonist) on pancreatic exocrine secretion in rats].
    Shiratori K; Watanabe S; Shimizu K; Moriyoshi Y; Chang JH; Takeuchi T
    Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):70-6. PubMed ID: 2471850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers.
    Schwarzendrube J; Niederau M; Lüthen R; Niederau C
    Gastroenterology; 1991 Jun; 100(6):1683-90. PubMed ID: 2019374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Duration of anti-cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally.
    Moriyoshi Y; Shiratori K; Iwabe C; Watanabe S; Takeuchi T
    J Gastroenterol; 1996 Apr; 31(2):249-53. PubMed ID: 8680546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.